Shares of UroGen Pharma (URGN) have resumed trading and are down $3.96, or 52%, to $3.59 after the Oncologic Drugs Advisory Committee of the U.S. Food and Drug Administration voted 4 to 5 that the benefit/risk of UGN-102 for intravesical solution was favorable for the treatment of recurrent LG-IR-NMIBC. “While we are disappointed by today’s outcome, we continue to believe our clinical data support UGN-102 for the treatment of recurrent LG-IR-NMIBC, a disease with no FDA-approved therapies,” said CEO Liz Barrett.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on URGN:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue